The Effect of Far-Infrared Therapy on the Peritoneal Expression of Glucose Degradation Products in Diabetic Patients on Peritoneal Dialysis

Chang, Chia Ning; Niu, Chih Yuan; Tan, Ann Charis; Chan, Che Chang; Chen, Chun-Fan; Chen, Tz Heng; Li, Szu Yuan; Chen, Yung Tai; Chen, Fan Yu; Liu, Wen Sheng; Lin, Chih Ching; Wei, Guor Jien

doi:10.3390/ijms22073732

Cited by 9 publications

(16 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, peritoneal dialysis combined with FIR can reduce the side effects of glucose in dialysis buffer, which interferes with peritoneal inflammation and peritoneal mesothelial cell fibrosis. This finding is in accordance with the literature [11].…”

Section: The Physiological Effect Of Peritoneal Dialysis Due To Firsupporting

confidence: 94%

“…Long-term exposure to non-biocompatible high-concentration glucose dialysate and repeated peritonitis are the main causes of changes in the structure and function of the peritoneum [4]. The glucose concentration of different dialysis buffers may impact the burden of kidney filtration rate [11]. Studies have shown that the glucose concentration also promotes peritoneal inflammation and the production of transforming growth factor by peritoneal mesothelial cells, finally leading to fibrosis [12].…”

Section: The Physiological Effect Of Peritoneal Dialysis Due To Firmentioning

confidence: 99%

“…Glucose degradation products (GDPs) contribute to reduced dialysis function and the pathogenesis of peritoneal membrane fibrosis [8,9,10]. A previous study showed that long-term exposure to non-biocompatible high-concentration glucose dialysate and repeated peritonitis are the main causes of changes in the structure and function of the peritoneum [4,11,12]. In summary, these factors induce proinflammatory hormones, such as interleukin-l beta (IL-1β), interleukin(IL), and tumor necrosis factor alpha (TNF-α), which triggers a persistent inflammatory response in the peritoneum, ultimately leading to structural changes in the peritoneum [13,14,15,16].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Peritonitis Recurrent in Peritoneal Dialysis Patients?

Chang¹,

Chang²,

Lee³

et al. 2022

Preprint

View full text Add to dashboard Cite

Introduction: The treatment of peritoneal dialysis in end-stage renal disease is increasing in clinical practice. The main purpose of this study was to evaluate the effect of far-infrared radiation therapy on inflammation and the cellular immunity of patients undergoing peritoneal dialysis. Materials and Methods: We recruited 56 patients undergoing peritoneal dialysis, and we included 32 patients from the experimental group and 24 patients from the control group in the final analysis. The experimental evaluation in our study was as follows: (1) We used abdominal computed tomography to measure the diameter and degree of hardening of the abdominal veins and large blood vessels to explore the changes in abdominal blood vessels. (2) The study compared the effects of peritoneal dialysis using albumin, blood urea nitrogen, creatinine, white blood cell, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, erythrocyte sedimentation rate, Hs-CRP clearance rate, and HBAlC. (3) We compared the cytokine concentration of blood between the two groups while controlling for GM-CSF, IL-2, IFN-γ, IL-6, IL-18, IL-4, IL-5, IL-13, IL-12p70, TNF-α, and IL-1β. Results and Discussion: (1) There was no significant difference in the abdominal blood vessels of the experimental group relative to the control group according to abdominal CT measured over 6 months. (2) Our study demonstrates the statistically significant effect of FIR therapy on the following parameters: albumin (p = 0.048*), creatinine (p = 0.039*), and Hs-CRP (p < 0.001**) decreased significantly, and glomerular filtration rate (eGFR, p = 0.043*) and glucose (p < 0.001**) increased significantly. Our study found that, in the experimental group, albumin and creatinine decreased significantly due to FIR therapy for 6 months. However, our study also found that, in the experimental group, glucose (p < 0.001**) increased significantly due to FIR therapy for 6 months. Peritoneal dialysis combined with FIR can reduce the side effects of glucose in dialysis buffer, which interferes with peritoneal inflammation and peritoneal mesothelial cell fibrosis. In addition, we also found that, in the experimental group, Hs-CRP (p < 0.001**) decreased significantly due to FIR therapy for 6 months. (3) No statistical significance in the inflammatory cytokines related to FIR therapy differences was observed in our study. IFN-γ (p = 0.124), IL-12p70 (p = 0.093), IL-18 (p = 0.213), and TNF-α (p = 0.254) did not exhibit significant improvements in peritoneal dialysis with FIR treatment over 6 months. IFN-γ and IL-18 in the plasma of patients in the experimental group and the control group were higher in the third month than in the first month. Conclusion: We found that the effect of peritoneal dialysis improved significantly with FIR therapy, and significant improvements in the peritoneal permeability and inflammatory response were observed. end-stage renal disease; peritoneal dialysis; far-infrared therapy (FIR)

show abstract

Section: The Physiological Effect Of Peritoneal Dialysis Due To Firsupporting

confidence: 94%

Section: The Physiological Effect Of Peritoneal Dialysis Due To Firmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Peritonitis Recurrent in Peritoneal Dialysis Patients?

Chang¹,

Chang²,

Lee³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Chang et al demonstrated that after the patients underwent 6 months of FIR therapy, 3 GDPs decreased significantly, namely methylglyoxal, furfural, and 5-hydroxymethyl-2-furaldehyde. Formaldehyde also exhibited a decreasing trend that approached borderline significance [ 17 ]. Previous studies have demonstrated that high levels of GDPs were linked to cellular damage, chronic inflammation, and oxidative stress [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

“…A case study showed that 3 months of FIR therapy alleviated a PD patient’s gastrointestinal symptoms due to encapsulating peritoneal sclerosis, a rare yet severe complication of PD, as well as improved his nutritional status and weight [ 16 ]. A recent study also showed that 6 months of FIR therapy may decrease dialysate GDPs in 31 ESRD patients on PD [ 17 ]. Due to limited literature, this study aims to investigate the long-term effect of FIR therapy on the peritoneal membrane transport characteristics of ESRD patients on PD.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Far-Infrared Therapy on the Peritoneal Membrane Transport Characteristics of Uremic Patients Undergoing Peritoneal Dialysis: An Open-Prospective Proof-of-Concept Study

Chen

Chan

et al. 2021

Membranes

Self Cite

View full text Add to dashboard Cite

Long-term peritoneal dialysis (PD) can lead to detrimental changes in peritoneal membrane function, which may be related to the accumulation of glucose degradation products. A previous study demonstrated that 6 months of far-infrared (FIR) therapy may decrease glucose degradation products in PD dialysate. Due to limited literature on this matter, this study aims to investigate the effect of FIR therapy on the peritoneal membrane transport characteristics of PD patients. Patients were grouped according to baseline peritoneal transport status: lower transporters (low and low-average) and higher transporters (high-average and high). Both groups underwent 40 min of FIR therapy twice daily for 1 year. In lower transporters, FIR therapy increased weekly dialysate creatinine clearance (6.91 L/wk/1.73 m2; p = 0.04) and D/P creatinine (0.05; p = 0.01). In higher transporters, FIR therapy decreased D/P creatinine (−0.05; p = 0.01) and increased D/D0 glucose (0.05; p = 0.006). Fifty percent of high transporter patients shifted to high-average status after FIR therapy. FIR therapy may decrease D/P creatinine for patients in the higher transporter group and cause high transporters to shift to high-average status, which suggests the potential of FIR therapy in improving peritoneal membrane function in PD patients.

show abstract

A Graphene Composite Film Based Wearable Far‐Infrared Therapy Apparatus (GRAFT) for Effective Prevention of Postoperative Peritoneal Adhesion

Lu,

Xu,

Song

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Postoperative peritoneal adhesion (PPA) is the most frequent complication after abdominal surgery. Current anti‐adhesion strategies largely rely on the use of physical separating barriers creating an interface blocking peritoneal adhesion, which cannot reduce inflammation and suffers from limited anti‐adhesion efficacy with unwanted side effects. Here, by exploiting the alternative activated macrophages to alleviate inflammation in adhesion development, a flexible graphene‐composite‐film (F‐GCF) generating far‐infrared (FIR) irradiation that effectively modulates the macrophage phenotype toward the anti‐inflammatory M2 type, resulting in reduced PPA formation, is designed. The anti‐adhesion effect of the FIR generated by F‐GCF is determined in the rat abdominal wall abrasion‐cecum defect models, which exhibit reduced incidence and area of PPA by 67.0% and 92.1% after FIR treatment without skin damage, significantly superior to the clinically used chitosan hydrogel. Notably, within peritoneal macrophages, FIR reduces inflammation reaction and promotes tissue plasminogen activator (t‐PA) level via the polarization of peritoneal macrophages through upregulating Nr4a2 expression. To facilitate clinical use, a wirelessly controlled, wearable, F‐GCF‐based FIR therapy apparatus (GRAFT) is further developed and its remarkable anti‐adhesion ability in the porcine PPA model is revealed. Collectively, the physical, biochemical, and in vivo preclinical data provide compelling evidence demonstrating the clinical‐translational value of FIR in PPA prevention.

show abstract

The Effect of Far-Infrared Therapy on the Peritoneal Expression of Glucose Degradation Products in Diabetic Patients on Peritoneal Dialysis

Cited by 9 publications

References 43 publications

Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Peritonitis Recurrent in Peritoneal Dialysis Patients?

Does Far-Infrared Therapy Improve Peritoneal Function and Reduce Peritonitis Recurrent in Peritoneal Dialysis Patients?

The Effect of Far-Infrared Therapy on the Peritoneal Membrane Transport Characteristics of Uremic Patients Undergoing Peritoneal Dialysis: An Open-Prospective Proof-of-Concept Study

A Graphene Composite Film Based Wearable Far‐Infrared Therapy Apparatus (GRAFT) for Effective Prevention of Postoperative Peritoneal Adhesion

Contact Info

Product

Resources

About